Evogene Reports Q1 Revenue of $300,000, Down from $2.3M Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Reports Q1 revenue $300,000 vs. $2.3M last year. As of March 31, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately $13.1M. The consolidated cash usage during the Q1 was approximately $2.8M. Ofer Haviv, President & CEO of Evogene, stated: "Following the strategic transformation initiated in 2025, we are now focused on execution and advancing our tech engine for small-molecule discovery and optimization, ChemPass AI, and expanding our product pipeline in pharma and agriculture, through collaborations and continued progress in our internal programs. ChemPass AI's competitive advantage lies in its ability to generate novel molecules while optimizing multiple critical parameters from the earliest stages of design. We continue to enhance the platform through internal development and collaboration with tech companies. In February 2026, we were proud to announce a second collaboration with Google Cloud focused on integrating advanced AI agents into ChemPass AI, aimed at automating the generation of unique datasets from complex scientific workflows, thereby enabling new capabilities in small-molecule discovery and optimization."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVGN
Wall Street analysts forecast EVGN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.715
Low
2.50
Averages
2.50
High
2.50
Current: 0.715
Low
2.50
Averages
2.50
High
2.50
About EVGN
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evogene Reports Q1 2026 Financial Results and Strategic Developments
- Financial Overview: Evogene reported revenues of $334,000 for Q1 2026, a significant drop from $2.34 million in Q1 2025, indicating challenges in revenue growth that may impact investor confidence.
- R&D Collaboration Expansion: The company announced three new collaborations in the pharmaceutical sector, bringing the total to four, demonstrating Evogene's ongoing commitment to advancing small-molecule discovery and optimization despite its poor financial performance.
- Agricultural Project Progress: The AgPlenus subsidiary is advancing novel herbicide programs through collaboration with Corteva, while its internal fungicide program shows strong progress, highlighting the effective integration of AI-driven design with experimental validation, potentially providing a competitive edge in the market.
- Strategic Transformation and Outlook: Following the strategic transformation initiated in 2025, Evogene is now focused on execution, expecting to support long-term growth through enhanced technological collaborations and product pipeline expansion, despite currently facing financial losses.
See More
Evogene Reports Q1 Earnings Miss with Significant Revenue Decline
- Earnings Performance: Evogene's Q1 GAAP EPS of -$0.60 misses expectations by $0.33, indicating significant challenges in profitability that could undermine investor confidence moving forward.
- Revenue Decline: The company reported revenue of $0.3M for the quarter, a staggering 100% year-over-year decline, falling short of the $0.05M forecast, reflecting severe market competition that may complicate future financing efforts.
- Cash Flow Situation: As of March 31, 2026, Evogene held approximately $13.1 million in cash and cash equivalents, with cash usage of about $2.8 million in Q1, highlighting increasing pressure on the company to maintain operations amid financial strain.
- Market Reaction Outlook: Given the poor financial performance, Evogene may face further scrutiny from Nasdaq, prompting investors to closely monitor the company's future financing and strategic adjustments to navigate its current financial challenges.
See More
Evogene to Announce Q1 Earnings on May 20
- Earnings Announcement Date: Evogene (EVGN) is set to announce its Q1 2023 earnings on May 20 before market open, with significant attention on its performance and future outlook.
- Expected Financial Metrics: Analysts project an EPS of -$0.27, reflecting a 28.9% year-over-year improvement, while revenue is estimated at $0.35 million, indicating a 100% year-over-year decline, highlighting the challenges the company faces.
- Historical Performance Review: Over the past two years, Evogene has beaten EPS estimates 63% of the time and revenue estimates 50% of the time, indicating a degree of volatility in its financial performance.
- Market Reaction Anticipation: Investors will closely monitor the upcoming earnings report to assess Evogene's financial health and competitiveness in the biotechnology sector, particularly in light of its performance in the current market environment.
See More
Evogene Faces Nasdaq Compliance Risk After Share Price Drop
- Compliance Risk Notification: Evogene Ltd. received a notice from Nasdaq indicating non-compliance with Rule 5550(a)(2) after its shares closed below $1.00 for 30 consecutive business days, potentially leading to delisting risks.
- Compliance Deadline: The company must regain compliance by September 28, 2026, requiring its shares to close at or above $1.00 for at least 10 consecutive business days within a 180-day period, which is critical for its financing and market confidence.
- Response Measures: Evogene stated it would consider options, including a potential reverse stock split, to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing.
- Market Reaction: Following the announcement, Evogene's shares fell by 3.16%, reflecting investor concerns about the company's ability to regain compliance, which could impact its financing capabilities and market image.
See More
Evogene Files Prospectus for Resale of 5.08M Shares
- Share Resale Plan: Evogene has filed a prospectus covering the resale of 5.08 million ordinary shares by a selling shareholder, which are issuable upon the exercise of warrants from a February 2026 inducement transaction, indicating the company's active engagement in capital markets.
- Warrant Details: The warrants involved include Series A-1 (5-year term) and Series B-1 (18-month term), both exercisable at $1.25 per share, reflecting the company's confidence in future stock price appreciation.
- Potential Revenue: Evogene expects to receive approximately $6.35 million if all warrants are exercised, which will provide additional financial support for the company's operations and R&D, enhancing its competitive position in the market.
- Selling Shareholder Gains: The selling shareholder may choose when to sell these shares and will receive all resale proceeds, a structure that could influence market liquidity and investor confidence in Evogene's stock.
See More
Evogene to Present at BIO-Europe Spring 2026 Conference
- Conference Appearance: Evogene Ltd. will present at the BIO-Europe Spring 2026 conference in Lisbon, Portugal, from March 23-25, showcasing its latest achievements in the pharma division, which is expected to attract industry attention and enhance the company's visibility.
- Technology Breakthrough Presentation: Chief Development Officer Dr. Gabi Tarcic and VP of Business Development Dr. Olga Nissan will highlight AI-driven small-molecule discovery and optimization technologies, emphasizing how ChemPass AI™ is enabling new collaborative drug discovery opportunities, potentially fostering partnerships with pharmaceutical and biotech firms.
- Presentation Schedule: Evogene's presentation is scheduled for March 24, 2026, from 15:30 to 15:45, under the theme “Drug Discovery and Development,” which not only showcases the company's technological prowess but may also attract potential investors' interest.
- One-on-One Meeting Opportunities: Both Dr. Tarcic and Dr. Nissan will be available for one-on-one meetings during the conference, encouraging interested parties to contact Evogene's investor or public relations team to facilitate deeper engagement and collaboration.
See More
Evogene Reports Q1 2026 Financial Results and Strategic Developments
- Financial Overview: Evogene reported revenues of $334,000 for Q1 2026, a significant drop from $2.34 million in Q1 2025, indicating challenges in revenue growth that may impact investor confidence.
- R&D Collaboration Expansion: The company announced three new collaborations in the pharmaceutical sector, bringing the total to four, demonstrating Evogene's ongoing commitment to advancing small-molecule discovery and optimization despite its poor financial performance.
- Agricultural Project Progress: The AgPlenus subsidiary is advancing novel herbicide programs through collaboration with Corteva, while its internal fungicide program shows strong progress, highlighting the effective integration of AI-driven design with experimental validation, potentially providing a competitive edge in the market.
- Strategic Transformation and Outlook: Following the strategic transformation initiated in 2025, Evogene is now focused on execution, expecting to support long-term growth through enhanced technological collaborations and product pipeline expansion, despite currently facing financial losses.
See More
Evogene Reports Q1 Earnings Miss with Significant Revenue Decline
- Earnings Performance: Evogene's Q1 GAAP EPS of -$0.60 misses expectations by $0.33, indicating significant challenges in profitability that could undermine investor confidence moving forward.
- Revenue Decline: The company reported revenue of $0.3M for the quarter, a staggering 100% year-over-year decline, falling short of the $0.05M forecast, reflecting severe market competition that may complicate future financing efforts.
- Cash Flow Situation: As of March 31, 2026, Evogene held approximately $13.1 million in cash and cash equivalents, with cash usage of about $2.8 million in Q1, highlighting increasing pressure on the company to maintain operations amid financial strain.
- Market Reaction Outlook: Given the poor financial performance, Evogene may face further scrutiny from Nasdaq, prompting investors to closely monitor the company's future financing and strategic adjustments to navigate its current financial challenges.
See More
Evogene to Announce Q1 Earnings on May 20
- Earnings Announcement Date: Evogene (EVGN) is set to announce its Q1 2023 earnings on May 20 before market open, with significant attention on its performance and future outlook.
- Expected Financial Metrics: Analysts project an EPS of -$0.27, reflecting a 28.9% year-over-year improvement, while revenue is estimated at $0.35 million, indicating a 100% year-over-year decline, highlighting the challenges the company faces.
- Historical Performance Review: Over the past two years, Evogene has beaten EPS estimates 63% of the time and revenue estimates 50% of the time, indicating a degree of volatility in its financial performance.
- Market Reaction Anticipation: Investors will closely monitor the upcoming earnings report to assess Evogene's financial health and competitiveness in the biotechnology sector, particularly in light of its performance in the current market environment.
See More
Evogene Faces Nasdaq Compliance Risk After Share Price Drop
- Compliance Risk Notification: Evogene Ltd. received a notice from Nasdaq indicating non-compliance with Rule 5550(a)(2) after its shares closed below $1.00 for 30 consecutive business days, potentially leading to delisting risks.
- Compliance Deadline: The company must regain compliance by September 28, 2026, requiring its shares to close at or above $1.00 for at least 10 consecutive business days within a 180-day period, which is critical for its financing and market confidence.
- Response Measures: Evogene stated it would consider options, including a potential reverse stock split, to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing.
- Market Reaction: Following the announcement, Evogene's shares fell by 3.16%, reflecting investor concerns about the company's ability to regain compliance, which could impact its financing capabilities and market image.
See More
Evogene Files Prospectus for Resale of 5.08M Shares
- Share Resale Plan: Evogene has filed a prospectus covering the resale of 5.08 million ordinary shares by a selling shareholder, which are issuable upon the exercise of warrants from a February 2026 inducement transaction, indicating the company's active engagement in capital markets.
- Warrant Details: The warrants involved include Series A-1 (5-year term) and Series B-1 (18-month term), both exercisable at $1.25 per share, reflecting the company's confidence in future stock price appreciation.
- Potential Revenue: Evogene expects to receive approximately $6.35 million if all warrants are exercised, which will provide additional financial support for the company's operations and R&D, enhancing its competitive position in the market.
- Selling Shareholder Gains: The selling shareholder may choose when to sell these shares and will receive all resale proceeds, a structure that could influence market liquidity and investor confidence in Evogene's stock.
See More
Evogene to Present at BIO-Europe Spring 2026 Conference
- Conference Appearance: Evogene Ltd. will present at the BIO-Europe Spring 2026 conference in Lisbon, Portugal, from March 23-25, showcasing its latest achievements in the pharma division, which is expected to attract industry attention and enhance the company's visibility.
- Technology Breakthrough Presentation: Chief Development Officer Dr. Gabi Tarcic and VP of Business Development Dr. Olga Nissan will highlight AI-driven small-molecule discovery and optimization technologies, emphasizing how ChemPass AI™ is enabling new collaborative drug discovery opportunities, potentially fostering partnerships with pharmaceutical and biotech firms.
- Presentation Schedule: Evogene's presentation is scheduled for March 24, 2026, from 15:30 to 15:45, under the theme “Drug Discovery and Development,” which not only showcases the company's technological prowess but may also attract potential investors' interest.
- One-on-One Meeting Opportunities: Both Dr. Tarcic and Dr. Nissan will be available for one-on-one meetings during the conference, encouraging interested parties to contact Evogene's investor or public relations team to facilitate deeper engagement and collaboration.
See More
